Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Waldenstrom Macroglobulinemia × Lisaftoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Waldenstrom Macroglobulinemia 1 Neuroblastoma 1 Leukemia, Prolymphocytic, T-Cell 1 Hematologic Neoplasms 1 Breast Neoplasms 1 Amyloidosis 1

Interventions

zanubrutinib 9 ibrutinib 9 Rituximab 5 idelalisib 4 pirtobrutinib 3 venetoclax 2 ublituximab 2 bazlitoran 2 acalabrutinib 2 Dexamethasone 2 ARQ531 2 umbralisib 1 selinexor 1 sapanisertib 1 pomalidomide 1 perifosine 1 pembrolizumab 1 ontuxizumab 1 ofatumumab 1 obinutuzumab 1 mavorixafor 1 loncastuximab tesirine 1 fludarabine 1 epratuzumab 1 enzastaurin 1 carfilzomib 1 brexucabtagene autoleucel 1 WW Domain-Containing Oxidoreductase 1 Voriconazole 1 Vitamin B 12 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡